Business
Positive Data from Vedanta IBD Clinical Studies
Positive Data from Vedanta IBD Clinical Studies.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 3247P\n PureTech Health PLC\n 09 June 2020\n \n \n \n \n 9 June 2020 \n \n \n PureTech Health plc\n \n \n \n PureTech Founded Entity Vedanta Biosciences Announces \n Positive \n Topline Data from Two Phase 1 Studies for IBD Candidate VE202\n \n \n \n \n \n VE202 was generally safe and well-tolerated in healthy volunteers, with durable and dose-dependent colonisation that will inform the Phase 2 dose regimen \n \n \n Vedanta has regained full rights to the programme and plans to advance it in a Phase 2 study within the next 12 months \n \n \n Company strengthens balance sheet with an additional $12 million in new equity and R&D collaboration funds, bringing the total Series C round to $71.1 million \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, \n \n is pleased to note that its Founded Entity, Vedanta Biosciences, today announced \n positive topline data from two Phase 1 studies in healthy volunteers of VE202, the company's orally-administered live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD). The studies showed that VE202 was generally safe and well-tolerated at all doses and demonstrated durable and dose-dependent colonisation. Vedanta expects to begin a Phase 2 study in IBD patients in the next 12 months. The trial was conducted by Janssen Research & Development, LLC; a more complete study dataset and analyses will be submitted to a peer-reviewed journal. Vedanta has regained full rights to the IBD programme and will owe Janssen single-digit royalty payments on net sales of a commercialised product.\n \n \n \n \n \n Vedanta also announced the receipt of $12 million in additional capital and R&D collaboration funds from new and existing investors, including JSR Corporation, bringing the total Series C/C-2 funding to $71.1 million. Participants in the total Series C round included the Bill & Melinda Gates Foundation, Bristol Myers Squibb, Rock Springs Capital, JSR Corporation, Shumway Capital, Health for Life (Seventure Partners), QUAD Investment Management, SV Investment Corp., Shinhan Investment-Private Equity, Shi...